Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | FABP1 | P07148 | 1/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | STAT3 | P40763 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.39 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.39 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9797523 | 0.84 | HSD11B1 (0.57) | PTGS2PTGS1HSD11B1FABP1SLC6A4 | |
| SCHEMBL313390 | 0.84 | ALDH1A1 (0.46) | PTGS2PTGS1ALDH1A1 | |
| SCHEMBL4202592 | 0.82 | PTGS2 (0.55) | PTGS2PTGS1SLC6A4SLC6A3ALDH1A1 | |
| SCHEMBL15879481 | 0.82 | PTGS2 (0.48) | PTGS2PTGS1NPC1ALDH1A1MAPT | |
| SCHEMBL2007711 | 0.81 | PTPRC (0.44) | PTGS2PTGS1SLC6A3NPC1ALDH1A1 | |
| SCHEMBL5682823 | 0.81 | CA12 (0.42) | PTGS2NPC1ALDH1A1MAPTRAB9A | |
| SCHEMBL778751 | 0.81 | PTGS2 (0.53) | PTGS2PTGS1HSD11B1FABP1SLC6A4 | |
| SCHEMBL2568289 | 0.81 | PTGS2 (0.68) | PTGS2PTGS1HSD11B1 | |
| SCHEMBL6904881 | 0.81 | PTGS2 (0.68) | PTGS2PTGS1HSD11B1SLC6A4SLC6A3 | |
| SCHEMBL14572631 | 0.80 | KIF11 (0.47) | HSD11B1MAPTMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORPORATION (FI) | 2012-08-02 | — | — | US | disclosed |
| US-7964643-B2 | Biphenyl-4-sulfonic acid-(4-hydroxybutyl)-amide and derivatives; inhibits osteoclast survival, formation, and/or activity and/or inhibits bone resorption; osteoporosis, rheumatoid arthritis, cancer associated bone disease, Paget's disease, antiinflammatory, -carcinogenic agents; immunostimulants | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2011-06-21 | — | — | US | disclosed |
| WO-2010146236-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | BIOTIE THERAPIES CORP. (FI) | 2010-12-23 | — | — | WO | disclosed |
| EP-1756046-B1 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | UNIV ABERDEEN (GB) | 2009-12-09 | — | — | EP | disclosed |
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2008-05-22 | — | — | US | disclosed |
| EP-1756046-A2 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | The University Court of The University of Aberdeen (GB) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118528-A2 | ARYL ALKYL SULFONAMIDES AS THERAPEUTIC AGENTS FOR THE TREATMENT OF BONE CONDITIONS | THE UNIVERSITY COURT OF THE UNIVERSITY OF ABERDEEN (GB) | 2005-12-15 | — | — | WO | disclosed |
| EP-0977733-B1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PROD INC (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6599890-B1 | Inhibitors of matrix metalloproteinases or the production of tumor necrosis factor | PFIZER INC | 2003-07-29 | — | — | US | disclosed |
| US-20020006920-A1 | Arylsulfonylamino hydroxamic acid derivatives | ROBINSON RALPH PELTON (US) | 2002-01-17 | — | — | US | disclosed |
| EP-1165501-A1 | ALKENYL- AND ALKYNYL-CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2002-01-02 | — | — | EP | disclosed |
| US-6303636-B1 | FOR THERAPY OF ARTHRITIS, CANCER, TISSUE ULCERATION, RESTENOSIS, PERIODONTAL DISEASE, EPIDERMOLYSIS BULLOSA, SCIERITIS, SEPSIS, SEPTIC SHOCK AND OTHER DISEASES INVOLVING THE PRODUCTION OF TUMOR NECROSIS FACTOR | PFIZER INC | 2001-10-16 | — | — | US | disclosed |
| US-6197770-B1 | ENZYME INHIBITORS; ANTIARTHRITIC AGENTS; BONE DISORDERS | THE PROCTER & GAMBLE CO. | 2001-03-06 | — | — | US | disclosed |
| WO-2000051975-A1 | ALKENYL- AND ALKYNYL-CONTAINING METALLOPROTEASE INHIBITORS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
| EP-0977733-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | Pfizer Products Inc. (US) | 2000-02-09 | — | — | EP | disclosed |
| EP-0960098-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES | PFIZER INC. (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998034918-A1 | ARYLSULFONYL HYDROXAMIC ACID DERIVATIVES | PFIZER INC. (US) | 1998-08-13 | — | — | WO | disclosed |
| WO-1998033768-A1 | ARYLSULFONYLAMINO HYDROXAMIC ACID DERIVATIVES | PFIZER PRODUCTS INC. (US) | 1998-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119555-A1 | Aryl Alkyl Sulfonamides As Therapeutic Agents For The Treatment Of Bone Conditions | ARSA, CNKSR1, BCL9L | PTGS2 2205/4885PTGS1 1037/4885HSD11B1 2062/4885 |
| US-20020006920-A1 | Arylsulfonylamino hydroxamic acid derivatives | MMP8, MMP1, MMP10 | PTGS2 224/4885PTGS1 84/4885HSD11B1 1294/4885 |
| US-20120196884-A1 | UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES | ITGA1, ITGB1, ITGA2B | PTGS2 676/4885PTGS1 391/4885HSD11B1 4268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.